Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406588 · ClinicalTrials.gov registry record · Phase 3
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
A Phase 3 study of Advanced Stage Parkinson's Disease, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT00406588: Completed Phase 3 study of Advanced Stage Parkinson's Disease, sponsored by Solvay Pharmaceuticals.
NCT00406588 is a Phase 3 study of Advanced Stage Parkinson's Disease that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 295 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00406588, a Phase 3 study of Advanced Stage Parkinson's Disease, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG Levodopa (Pardoprunox)
Study Locations (20)
Other
- Site 100 - Buenos Aires
- Site 101 - Buenos Aires
- Site 102 - Buenos Aires
- Site 103 - Buenos Aires
- Site 106 - Buenos Aires
Florida
- Site 214 - Fort Lauderdale
- Site 218 - Gainsville
- Site 213 - Tampa
California
- Site 220 - La Jolla
- Site 211 - San Francisco
Alabama
- Site 223 - Birmingham
Georgia
- Site 219 - Augusta
Illinois
- Site 221 - Chicago
Kansas
- Site 216 - Kansas City
Kentucky
- Site 224 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
What the finished NCT00406588 record still lists
NCT00406588 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Advanced Stage Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00406588 names 20 study sites across 13 states, led by Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00406588 about?
NCT00406588 is a clinical study titled "SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations". This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to ...
What is the current status of trial NCT00406588?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 295 participants. The study started on 2007-03. Estimated completion is 2008-05.
What conditions does trial NCT00406588 study?
This clinical trial studies the following conditions: Advanced Stage Parkinson's Disease.
What interventions are being tested in trial NCT00406588?
The interventions under investigation include: Placebo Comparator (DRUG), Levodopa (Pardoprunox) (DRUG).
Who is sponsoring clinical trial NCT00406588?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406588 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00406588's enrollment target sits among peer trials
295 1166th of 2000 higher than 835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia